 Aeglea BioTherapeutics, Inc. AGLE, a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases, today announced a proposed underwritten public offering in which it intends to offer and sell 100 million 